SOPHiA GENETICS logo

SOPHiA GENETICS(NASDAQ) SOPH

Market Cap$630.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-56%
5 Year-55%
1 Year+63%
1 Month-4%
Premium Feature
Moneyball Superscore
72/100
$7.40
+1.37%
+0.10Today
After hours$7.40+$0.00 (+0.00%)
SOPHiA GENETICS last closing stock price
MetricPriceDate
Last closeUSD 7.412026-10-09
SOPHiA GENETICS stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.18%USD 8.072026-10-02
1 month-3.52%USD 7.682026-09-09
3 month+31.15%USD 5.652026-07-10
Year to date+58.67%USD 4.672025-12-31
1 year+62.5%USD 4.562025-10-09
3 year+188.33%USD 2.572023-10-10
5 year-54.82%USD 16.402021-10-08
Since inception-55.79%USD 16.762021-07-23

SOPHiA GENETICS Financials at a Glance

Market Cap

$630.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$86.17M

Net Income (TTM)

-$80.88M

EPS (TTM)

-$1.15

P/E Ratio

-6.44

Dividend

$0.00

Beta (Volatility)

1.09 (Average)

Price

$7.40

Volume

328,118.46

Open

$7.32

Previous Close

$7.41

Daily Range

$7.07 - $7.46

52-Week Range

$3.75 - $8.98

Estimated Earnings Date

Nov 3, 2026

SOPH News

No articles available.

SOPH: Motley Fool Moneyball Superscore

72

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About SOPHiA GENETICS

SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various diagnostic inputs, thereby extracting valuable insights. This platform is widely adopted by hospitals, laboratories, and biopharmaceutical organizations across the globe.

Products and Services
  • SOPHiA DDM platform for data analysis and insights
  • Cloud-native SaaS solutions for healthcare applications
  • Support and consulting services for implementation
Growth Outlook
  • Revenue increased to $23.31 million in Q2 2026
  • Gross profit margin improved to 64.6% in Q2 2026
  • Strong cash position with $107.67 million in cash and equivalents
Financial Highlights
  • Trailing twelve months (TTM) revenue of $88.88 million
  • Operating loss of $20.05 million in Q2 2026
  • Current ratio of 2.69 indicates strong liquidity
SOPHiA GENETICS S.A. has established itself as a leader in the healthcare technology sector, particularly with its innovative SOPHiA DDM platform. The company has shown promising growth, with a notable increase in revenue and an improved gross profit margin, reflecting its ability to generate value from its offerings. The strong cash position provides a solid foundation for future investments and operational stability. Despite facing operating losses, the current ratio indicates that the company is well-positioned to meet its short-term obligations. Overall, SOPHiA GENETICS S.A. presents a compelling opportunity for investors interested in the intersection of technology and healthcare.
AI Generated • Sep 22, 2026

Industry

Health Care Technology

Sector

Health Care

Employees

415

CEO

Jurgi Camblong, PhD, EMBA

Website

www.sophiagenetics.com

Headquarters

Rolle, VD 1180, CH

SOPH Financials

Key Financial Metrics (TTM)

Gross Margin

66.63%

Operating Margin

-85.01%

Net Income Margin

-93.86%

Return on Equity

-136.71%

Return on Capital

-64.38%

Return on Assets

-40.77%

Earnings Yield

-15.53%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$630.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

85.13M

Volume

328.12K

Avg. Volume

546.57K

Financials (TTM)

Gross Profit

$57.41M

Operating Income

-$73.25M

EBITDA

-$63.78M

Operating Cash Flow

-$41.60M

Capital Expenditure

-$4.03M

Free Cash Flow

-$45.63M

Cash & ST Invst.

$107.67M

Total Debt

$61.83M

SOPHiA GENETICS Performance Analysis

SOPHiA GENETICS annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 47,560,00017.6%
20232023-12-31USD 62,371,00031.1%
20242024-12-31USD 65,173,0004.5%
20252025-12-31USD 77,271,00018.6%
SOPHiA GENETICS sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-306.2%
Q42025-12-3111.5%
Q12026-03-31-0.1%
Q22026-06-307.5%
SOPHiA GENETICS annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.3618.3%
20232023-12-31USD -1.22-10.6%
20242024-12-31USD -0.95-22.4%
20252025-12-31USD -1.1723.6%
SOPHiA GENETICS sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-309.1%
Q42025-12-316.7%
Q12026-03-313.6%
Q22026-06-30-11.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$23.31M

+27.2%

Gross Profit

$15.06M

+22.7%

Gross Margin

64.61%

N/A

Market Cap

$630.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.52M

N/A

Employees

415

N/A

Net Income

-$22.36M

+0.3%

EBITDA

-$17.75M

+5.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$107.67M

+13.5%

Total Debt

$61.83M

-3.1%

Accounts Receivable

$14.11M

+48.5%

Inventory

$7.08M

+13.9%

Long Term Debt

$59.11M

-3.6%

Short Term Debt

$2.72M

+9.5%

Return on Assets

-40.77%

N/A

Return on Invested Capital

-49.73%

N/A

Free Cash Flow

-$10.39M

-2.0%

Operating Cash Flow

-$7.69M

+6.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NRCNRC Health
$20.33-0.44%
HSTMHealthStream, Inc.
$33.13+2.03%
OPRXOptimizeRx Corp.
$8.28-1.19%
HCATHealth Catalyst, Inc.
$1.77+1.14%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About SOPH

What is the current price of SOPHiA GENETICS?

SOPHiA GENETICS is trading at $7.41 per share.

What is the 52-week range for SOPHiA GENETICS?

Over the past 52 weeks, SOPHiA GENETICS has traded between $3.75 and $8.98.

How much debt does SOPHiA GENETICS have?

As of the most recent reporting period, SOPHiA GENETICS reported total debt of $61.83M.

How much cash does SOPHiA GENETICS have on hand?

SOPHiA GENETICS reported $107.67M in cash and cash equivalents in its most recent financial results.

What is SOPHiA GENETICS’s dividend yield?

SOPHiA GENETICS does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services